Trial Profile

Deliver Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World: United States Prospective Registry Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 26 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavacamten (Primary) ; Beta adrenergic receptor antagonists; Disopyramide
Indications Hypertrophic cardiomyopathy
Focus Therapeutic Use
Acronyms DISCOVER-HCM
Sponsors Bristol-Myers Squibb

Most Recent Events

12 Jun 2026 Planned number of patients changed from 1500 to 1700.
23 Mar 2026 According to Bristol Myers Squibb media release, data from this trial will be presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo, taking place March 28-30, 2026, in New Orleans, Louisiana.
17 Dec 2024 Planned End Date changed from 15 Aug 2029 to 17 Aug 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com